BackImmunovant Overview

Immunovant Operating Income

Operating Income for IMVT.

Quarterly Operating Income

$-159554000.00
↓ 149.2% YoY

As of Mar 31, 2026

Annual Operating Income (TTM)

$-418540000.00
↓ 6345% YoY

Trailing 12 months ending Mar 31, 2026

Average Operating Income (Comparison Companies)

Operating Income History

Operating Income Comparison

Annual Operating Income Growth Rate (%)

Annual Operating Income Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin